BD finished fiscal 2026 with higher revenue, adjusted earnings and cash generation, while setting low single-digit growth expectations for the year ahead. Its proposed US$19 billion US investment adds scale to the strategy, but remains tied to milestones and future implementation.
- Fiscal 2026 revenue rose 4.9% to US$19.5 billion
- Adjusted diluted EPS increased to US$12.70
- Free cash flow climbed 42.5% to US$2.9 billion
- Fiscal 2027 guidance calls for low single-digit revenue growth and adjusted EPS of US$13.10 to US$13.30
- Planned US$19 billion US investment includes US$3 billion for manufacturing expansion
Becton, Dickinson and Company (NYSE:BDX) is entering fiscal 2027 with a cleaner portfolio, sharply stronger cash generation and an ambitious US manufacturing pledge. The medical technology company reported fiscal 2026 revenue of US$19.5 billion, up 4.9% on a reported basis, while free cash flow jumped 42.5% to US$2.9 billion.
Fiscal 2026 growth broadens beyond the headline
Fourth-quarter revenue rose 5.4% to US$5.274 billion, or 5.6% excluding foreign exchange effects. Interventional was the fastest-growing major segment, with revenue up 7.6% on both reported and currency-neutral measures, followed by BioPharma Systems at 6.5% reported growth and Medical Essentials at 5.9%. Connected Care was the laggard, increasing 1.6% as reported and 2.1% on a currency-neutral basis.
The earnings picture improved materially on continuing operations. Fourth-quarter GAAP diluted earnings per share rose to US$2.52 from US$1.20, while adjusted diluted EPS increased 27.3% to US$4.15. For the full year, GAAP diluted EPS was US$5.06 and adjusted diluted EPS was US$12.70. The adjusted figure excludes items including purchase-accounting adjustments, restructuring, separation costs, legal matters and other specified charges, so the two measures describe distinctly different versions of fiscal performance.
New BD targets modest growth after portfolio reshaping
BD’s fiscal 2027 guidance calls for low single-digit revenue growth both on a reported and foreign currency-neutral basis, with adjusted diluted EPS of US$13.10 to US$13.30. That represents a 3.1% to 4.7% increase against fiscal 2026 adjusted EPS, according to the company’s reconciliation. BD has not provided a comparable GAAP EPS outlook because the timing and size of future amortisation, acquisition, separation and other charges cannot be estimated without unreasonable effort.
The guidance follows the February separation of BD’s former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. Historical figures have been recast as continuing operations, meaning comparisons now describe a smaller, more focused BD rather than the pre-separation group. Fiscal 2026 also included US$642 million of restructuring costs, including US$450 million in non-cash asset impairments, as the company exited activities it said no longer fitted its strategy.
US$19 billion investment carries strategic and execution questions
Alongside the results, BD highlighted a partnership with the US Government under which it intends to invest US$19 billion in the United States over several years. The plan includes US$3 billion for manufacturing expansion and other capital, operating and supply-chain spending. The agreement also provides relief from future Section 232 tariffs on covered products and inputs, although that relief depends on the final scope of future actions and BD meeting agreed milestones.
The company also pointed to product and clinical milestones across interventional care and tissue regeneration, including the US launch of its Liverty TIPS Stent Graft, nine-month results from the iliac cohort of the AGILITY trial, and completed enrolment in the PREVENT trial for hernia prevention. Those developments add potential growth avenues, but the filing does not attach revenue forecasts to the individual products or studies. The more immediate test is whether the reshaped portfolio can convert fiscal 2026’s cash-flow improvement into the low single-digit growth and adjusted earnings expansion promised for fiscal 2027.
Bottom Line?
BD has improved its financial footing, but the next year will test whether portfolio simplification and a large US investment can produce growth without bringing back heavy restructuring costs.
Questions in the middle?
- How much of the proposed US$19 billion investment will be deployed in fiscal 2027, and what funding mix will support it?
- What assumptions underpin the low single-digit revenue outlook across Interventional, Medical Essentials, Connected Care and BioPharma Systems?
- Will tariff relief and completed clinical milestones translate into measurable margin or revenue benefits, or remain longer-term strategic options?